This is the authors' abstract. We don't add key points for this paper.
Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BCL-XL antagonists containing an undesirable hydrazone functionality, in silico design and X-ray crystallography were utilized to develop alternative scaffolds that retained the selectivity and potency of the starting compounds.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Koehler et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: